The app, called Kaia COPD, provides a lung rehab program to enhance physical efficiency and lifestyle for individuals with the persistent inflammatory illness of the lungs.
It now has actually been authorized in Germany as part of the digital health application (DiGA) directory site of the German Federal Institute for Drugs and Medical Devices (BfArM).
“The bar for approval by BfArM is exceptionally high and this approval is a testament to our commitment to both clinical excellence and developing solutions that enable easy access to care and are cost-effective,” Nigel Ohrenstein, president of Kaia Health, said in a news release.
The app’s accessibility in Germany follows its rollout in 2015 in North America. According to the business, the Kaia COPD app is now available to more than 73 million clients around the world.
The AMOPUR scientific trial (NCT04299165), carried out in Switzerland and Germany, examined whether the app assisted COPD clients to carry out physical and breathing workouts in their houses as part of a lung rehab regimen.
Patients had actually ended up an in-hospital lung rehabilitation program prior to registering. They then were arbitrarily designated to continue lung rehab with Kaia COPD or to relocate to basic care, with that group functioning as controls.
Results gathered after 6 months revealed that clients designated to the Kaia COPD app had substantially greater levels of exercise when compared to clients in the control group. Symptom intensity, consisting of shortness of breath and tiredness, likewise minimized in those utilizing the app compared to controls.
It is so vital for COPD clients to stay active to enhance their health-related lifestyle, and I more than happy to see that Kaia COPD as an efficient and practical treatment alternative is now available to much more clients in the future.
“I see the effects of COPD on the quality of life of my patients every single day. Our research has shown that the Kaia COPD app helps sustain the positive effects of pulmonary rehabilitation,” said Rembert Koczulla, MD, a leading pulmonology expert at the Schön Klinik Berchtesgadener Land, in Germany, and co-author of the research study reporting information from the AMOPUR trial.
“It is so critical for COPD patients to remain active to improve their health-related quality of life, and I am happy to see that Kaia COPD as an effective and convenient treatment option is now available to even more patients in the future,” Koczulla said.
The effectiveness of the Kaia COPD app likewise was shown in an organized information analysis carried out in Germany that included 104 clients. This analysis showed that, throughout 3 months, clients utilizing the app experienced considerable enhancements in health-related lifestyle and physical efficiency.
“We will continue to deliver on our mission to make clinically proven, affordable solutions available to patients anywhere, anytime that will dramatically improve their quality of life,” Ohrenstein said.
